

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

UPDATE ON THE SUPPLEMENTAL AGREEMENT TO THE LOAN AGREEMENT AND POSSIBLE CHANGE IN CONTROLLING SHAREHOLDER

Reference is made to the Company's announcement dated 27 March 2019 (the "**Announcement**") in relation to the Supplemental Agreement and the possible change in its controlling shareholder. The Board wishes to provide shareholders and investors with an update to the Supplemental Agreement. Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, under the Supplemental Agreement, the maturity date of the Loan would be extended from 30 April 2019 to 30 April 2020, subject to certain conditions precedent, one of which relates to the Transfers by Risun to the New Lenders for partial settlement of the Loan (the "**Transfers Condition Precedent**"). Subsequent to the signing of the Supplemental Agreement, the Transfers Condition Precedent was waived by Mr. Gui and the New Lenders, and hence, the Transfers were not executed and will not take place pursuant to the Supplemental Agreement.

On 29 March 2019, as all conditions precedent to the Supplemental Agreement were either waived or fulfilled (including the waiver of the Transfers Condition Precedent), the Supplemental Agreement was completed and the maturity date of the Loan was extended from 30 April 2019 to 30 April 2020.

Furthermore, given that the Transfers were not executed and they will not take place pursuant to the Supplemental Agreement, as at the date of this announcement, each of Risun and Mr. Huang remains as the Company's controlling shareholder and they are interested in 1,050,000,000 Shares, representing approximately 62.06% of the Company's total issued share capital, of which, 1,049,990,000 Shares remain to be charged to Mr. Gui pursuant to the Loan Agreement.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 9 April 2019

As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive directors of the Company are Mr. Wang Qing, Mr. Liu Wenfang and Mr. Lau Ying Kit.